Quizartinib for Newly Diagnosed <i>FLT3</i> -Internal Tandem Duplication–Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI StudyPau Montesinos, Jorge Labrador, María Calbacho et al.|Journal of Clinical Oncology|2025Cited by 13
Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed <i>FLT3</i>-ITD Negative AMLPau Montesinos, Jorge Labrador, Rebeca Rodríguez‐Veiga et al.|Blood|2024Cited by 5
Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic RegistryDavid Martínez‐Cuadrón, Pau Montesinos, Blanca Boluda et al.|Blood|2023Cited by 2
Erratum: Quizartinib for Newly Diagnosed <i>FLT3</i> -Internal Tandem Duplication–Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI StudyPau Montesinos, Jorge Labrador, Rebeca Rodríguez‐Veiga et al.|Journal of Clinical Oncology|2025Cited by 1